<DOC>
	<DOCNO>NCT00757042</DOCNO>
	<brief_summary>This study phase 1 single dose escalation study AMG 157 healthy subject subject moderate severe atopic dermatitis . The purpose study evaluate safety , tolerability pharmacokinetics AMG 157 .</brief_summary>
	<brief_title>Safety Study AMG 157 Healthy Subjects Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subject must sign Institutional Review Board ( IRB ) approve informed consent form study specific procedure Subjects must age 18 45 year , inclusive ( Part A ) Female subject must nonreproductive potential Male subject partner childbearing potential inform partner participation clinical study use highly effective method birth control study Healthy subject must body mass index ( BMI ) 18 32 kg/m2 , inclusive Subject must normal clinically acceptable physical examination , clinical laboratory test electrocardiogram ( ECG ) result For Part B , Subject must active AD affect ≥10 % body surface area ; EASI score ≥15 , age 18 60 year , inclusive BMI 18 35 kg/m2 , inclusive Subject history evidence clinically significant disorder , condition disease , opinion Investigator consultation Amgen physician , would pose risk subject safety interfere study evaluation , procedures completion Subject evidence active suspect bacterial , viral , fungal parasitic infection within past 30 day prior randomization Subject know positive tuberculin skin test recent ( within 6 month randomization ) exposure individual active tuberculosis Subject history malignancy within 5 year randomization Subject history significant dermatological condition ( except atopic dermatitis Part B ) Subject previously receive investigational drug ( currently use investigational device ) within 30 day prior randomization Subject test positive drug and/or alcohol use screen randomization Female subject pregnant lactate Subject use nicotine tobacco contain product 6 month randomization study ( except Part B ) For atopic dermatitis subject Part B ( Cohorts 9 10 ) , additional exclusion criterion follow : Subject concurrent skin disease ( eg , acne ) severity study area could interfere study evaluation ; Subject active recent skin infection ( within 7 day randomization ) ; Subject receive phototherapy ( eg , UVA , UVB ) know suspected effect AD within 6 week prior randomization ; Subject receive corticosteroid topical , inhaled intranasal delivery within 4 week prior randomization ; Subject treat topical calcineurin inhibitor within 14 day prior randomization ; Subject us medication interfere blood coagulation ( eg NSAIDs ) wind heal within 7 day 5 halflives ( whichever longer ) prior enrol study duration study . Subject smoke 10 cigarette per day within 6 month prior randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>skin disease</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>